# 💊 Medical Management

## 🎯 PREVENT-Guided Treatment Decisions

The 2025 guidelines fundamentally restructure treatment decisions using the **PREVENT calculator** with the unified **7.5% threshold** for Stage 1 hypertension, aligning cardiovascular risk reduction strategies with statin therapy recommendations.

## 📊 Treatment Thresholds Using PREVENT

### 🎯 Unified 7.5% Risk Threshold

The 7.5% threshold represents deliberate alignment with statin therapy thresholds, promoting unified cardiovascular risk reduction strategies.

#### Stage 1 HTN + PREVENT ≥7.5%

Class 1: Immediate medication

#### Stage 1 HTN + PREVENT \<7.5%

Class 1: Medication after 3-6 month lifestyle trial

#### Stage 2 HTN

Class 1: Immediate dual therapy

## 🏗️ First-Line Agent Selection

First-line agent selection maintains thiazide-type diuretics, long-acting dihydropyridine calcium channel blockers, ACE inhibitors, and ARBs as Class 1 recommendations based on cardiovascular outcome trials.

### 💧 Thiazide-Type Diuretics

**Preferred:** Chlorthalidone over HCTZ for superior potency

#### Dosing

**Chlorthalidone:** 12.5-25 mg daily **Indapamide:** 1.25-2.5 mg daily **HCTZ:** 25-50 mg daily (less preferred)

#### ✓ Advantages

- Excellent CV outcomes
- Low cost
- Synergistic

#### 📋 Monitoring

- K+, Na+, Mg2+
- Creatinine
- Glucose, uric acid

### 🛡️ ACE Inhibitors / ARBs

**RAAS Blockade:** Preferred for diabetes, CKD, or HF

#### ACE Inhibitors

**Lisinopril:** 10-40 mg **Enalapril:** 5-20 mg BID **Ramipril:** 2.5-10 mg

#### ARBs

**Losartan:** 50-100 mg **Olmesartan:** 20-40 mg **Telmisartan:** 40-80 mg

#### ⭐ Special Indications

Diabetic kidney disease HFrEF Post-MI CKD

### 🔄 Calcium Channel Blockers

**DHPs:** Long-acting formulations preferred

#### Long-Acting DHPs

**Amlodipine:** 2.5-10 mg **Nifedipine XL:** 30-90 mg **Felodipine:** 2.5-10 mg

#### Non-DHPs

**Diltiazem:** 120-360 mg **Verapamil:** 120-480 mg Rate control option

#### 💡 Clinical Pearls

- Excellent for isolated systolic HTN
- Safe in CKD • Monitor for edema
- **Avoid** immediate-release nifedipine

### 💓 Beta-Blockers

**Reserved:** Not first-line unless compelling indication

#### ⭐ Compelling Indications

HFrEF Post-MI Angina / AFib rate control

#### Preferred Agents

**Metoprolol XL:** 25-200 mg **Carvedilol:** 3.125-25 BID **Bisoprolol:** 2.5-10 mg

#### ⚠️ Limitations

- Less effective for stroke prevention
- Metabolic effects • Contraindicated in severe asthma
- May mask hypoglycemia

## 🤝 Combination Therapy Strategy

CLASS 1

### Initial Dual Therapy for Stage 2 HTN

Combination therapy achieves target BP **6 months faster** with fewer adverse events than sequential monotherapy titration.

#### 🎯 Preferred Combinations

✓ ACEi/ARB + Thiazide ✓ ACEi/ARB + CCB ✓ CCB + Thiazide

#### 📦 Single-Pill Combinations

20-25%

Better adherence vs separate tablets

- Simplified dosing regimens
- Cost-effective long-term
- Reduced pill burden

#### ⚡ Clinical Advantages

⏱️ Faster time to goal BP 🔗 Synergistic mechanisms ✨ Fewer dose-related side effects 📈 Improved long-term outcomes CLASS 3 HARM

### 🚫 Dual RAAS Blockade

Increased hyperkalemia, hypotension, and AKI without CV benefit (ONTARGET, ALTITUDE trials)

#### ❌ Prohibited Combinations

✗ ACE inhibitor + ARB ✗ ACEi/ARB + Direct renin inhibitor ✗ Triple RAAS blockade

#### ⚠️ Increased Risks

🔺 Hyperkalemia\
K+ \>5.5 📉 Hypotension 🩺 Acute Kidney\
Injury 💫 Syncope\
& Falls

#### 📊 Trial Evidence

**ONTARGET**

No CV benefit with dual blockade

**ALTITUDE**

Increased harm, trial stopped early

⚠️ FDA & EMA Warnings

## 🎯 Blood Pressure Goals

\<130/80 mmHg STANDARD TARGET

**Universal Goal:** All high-risk patients before considering intensification

#### High-Risk Criteria

PREVENT ≥7.5% Clinical CVD Diabetes CKD \<120 mmHg Systolic INTENSIVE TARGET SPRINT Evidence 25% ↓ CV events • 27% ↓ mortality

#### ✓ Select For

- Age ≥50 + high CV risk
- No diabetes
- No prior stroke

#### ✗ Exclude

- Frail elderly
- Orthostatic HTN
- Limited life expectancy

⚖️ Shared Decision Making INDIVIDUALIZED

#### 🤔 Consider

- Comorbidity burden
- Medication tolerance
- Patient preferences
- Quality of life

#### 📋 Monitor

- Regular BP checks
- Orthostatic BP
- Kidney function
- Electrolytes

## 🧮 Interactive Treatment Decision Tool

### Treatment Threshold Calculator

Blood Pressure Stage: PREVENT Risk Score (%): 5.0% Comorbidities: Diabetes CKD CVD Heart Failure

#### Treatment Recommendation

Based on current inputs, lifestyle modifications are recommended.

##### Preferred Initial Therapy:

Lifestyle modifications first

##### Target Blood Pressure:

\<130/80 mmHg

### 🎯 Key Implementation Strategies

#### 📊 PREVENT Integration

Use PREVENT calculator for all Stage 1 hypertension treatment decisions. The 7.5% threshold aligns with statin recommendations for unified cardiovascular risk reduction.

#### 💊 Combination Priority

Start dual therapy for Stage 2 hypertension. Single-pill combinations improve adherence by 20-25% compared to separate tablets.

#### 🎯 Goal Achievement

Achieve \<130/80 mmHg in all high-risk patients. Consider intensive targets (\<120 mmHg) only in carefully selected patients without contraindications.

## 📚 Sources

1.  **Whelton PK, et al.** 2017 ACC/AHA HTN Guideline. *Hypertension.* 2018;71(6):e13-e115. [PMID: 29133356](https://pubmed.ncbi.nlm.nih.gov/29133356/).
2.  **SPRINT Research Group.** Intensive vs Standard BP Control. *N Engl J Med.* 2015;373(22):2103-2116. [PMID: 26551272](https://pubmed.ncbi.nlm.nih.gov/26551272/).
3.  **ALLHAT Officers.** ALLHAT trial. *JAMA.* 2002;288(23):2981-2997. [PMID: 12479763](https://pubmed.ncbi.nlm.nih.gov/12479763/).
4.  **Ettehad D, et al.** BP lowering meta-analysis. *Lancet.* 2016;387(10022):957-967. [PMID: 26724178](https://pubmed.ncbi.nlm.nih.gov/26724178/).
5.  **Cameron NA, Jones DW, Khan SS, Lloyd-Jones DM.** 2025 AHA/ACC HTN Guideline Case Applications. *Hypertension.* 2025;82(12):2055-2063. [PMID: 41204807](https://pubmed.ncbi.nlm.nih.gov/41204807/).

📚 For Educational Purposes Only

© 2025 University of Dubuque PA Program - All Rights Reserved


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/medical-management.html) · Markdown synchronized October 3, 2026.